Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02581215 · ClinicalTrials.gov registry record · Phase 2

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

A Phase 2 study of Pancreatic Cancer, sponsored by Walid Shaib, MD.

Completed
Registry status
Phase 2
Development phase
84
Enrollment target
8
Study locations

NCT02581215 is a Phase 2 study of Pancreatic Cancer that has completed, run by Walid Shaib, MD. The registered enrollment target is 84 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (79% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02581215, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Walid Shaib, MD.

COMPLETED
Registry status
Phase 2
Development phase
84 participants
Enrollment target
8
Study locations

Study Summary

This is a phase II, multicenter, double-blinded, randomized, 2-arm trial evaluating the efficacy and safety of mFOLFIRINOX plus ramucirumab (Arm A) vs. mFOLFIRINOX plus placebo (Arm B) in 94 subjects with advanced pancreatic cancer, not amenable to curative treatment. Both arms will continue treatment until disease progression or unacceptable toxicity.

Conditions Studied

Pancreatic Cancer

Interventions

  • OTHER Placebo
  • DRUG mFOLFIRINOX
  • DRUG Ramucirumab

Study Locations (8)

Indiana

  • Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
  • Community Healthcare System - Munster

Pennsylvania

  • Gettysburg Cancer Center - Gettysburg
  • Thomas Jefferson University Kimmel Cancer Center - Philadelphia

Arizona

  • Mayo Clinic-Arizona - Scottsdale

Georgia

  • Emory University: Winship Cancer Institute - Atlanta

Kentucky

  • University of Louisville, James Graham Brown Cancer Center - Louisville

Nebraska

  • Nebraska Methodist Hospital - Omaha

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2016-09-11
Est. Completion 2022-01-27
Phase Phase 2

Sponsor

Walid Shaib, MD

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02581215

The ClinicalTrials.gov registry entry for NCT02581215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (79% lower). The listed sponsor is Walid Shaib, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02581215 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Indiana, Pennsylvania, Arizona.

Frequently Asked Questions

What is clinical trial NCT02581215 about?

NCT02581215 is a clinical study titled "Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer". This is a phase II, multicenter, double-blinded, randomized, 2-arm trial evaluating the efficacy and safety of mFOLFIRINOX plus ramucirumab (Arm A) vs. mFOLFIRINOX plus placebo (Arm B) in 94 subjects with advanced pancreatic cancer, not amenable to curative treatment. Both arms will continue treatme...

What is the current status of trial NCT02581215?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2016-09-11. Estimated completion is 2022-01-27.

What conditions does trial NCT02581215 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT02581215?

The interventions under investigation include: Placebo (OTHER), mFOLFIRINOX (DRUG), Ramucirumab (DRUG).

Who is sponsoring clinical trial NCT02581215?

This trial is sponsored by Walid Shaib, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02581215 being conducted?

This trial has 8 study locations across Arizona, Georgia, Indiana, Kentucky, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.